TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04594408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1 mL of 1:1000 mixed into irrigation bag.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1 g IV x 1 dose to be administered intraoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Tranexamic Acid
Description: 1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
Study: NCT03880227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess visual attention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess visual attention
Study: NCT03382171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoodforCare at home
Description: Five small protein rich meals that will be delivered twice a week for 3 weeks.
Study: NCT01034475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is \>Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme.
Study: NCT01219465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Study: NCT03196557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on dose on specified days
Study: NCT01608906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose intravenous heparin (LDIVH)
Description: The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
Study: NCT03880227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention
Study: NCT00666614

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Environment Intervention
Description: Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Hospital Environment
Description: Normal Hospital Environment
Study: NCT00088881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET scans
Study: NCT00688493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose
Study: NCT01949675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration
Study: NCT04562805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynamX Bioadaptor
Description: DynamX Bioadaptor Treatment
Study: NCT00688493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose
Study: NCT01949675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration
Study: NCT00688493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose
Study: NCT03359681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Study: NCT00688493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study: NCT03359681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Study: NCT00688493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study: NCT04562805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx
Description: Resolute Onyx Treatment
Study: NCT01901549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation
Description: The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
Study: NCT00688493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study: NCT01901549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
Study: NCT00688493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study: NCT03344159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for a total of duration of 12 weeks
Study: NCT01901549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
Study: NCT03761914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: galinpepimut-S
Description: * Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: galinpepimut-S
Description: * Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone.
Study: NCT02082834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal MDCT examination
Study: NCT02928627

Intervention type: OTHER
Intervention: Analysis of microRNA expression
Description: sample analysis

Intervention type: OTHER
Intervention: Analysis of microRNA expression
Description: sample analysis
Study: NCT01597349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Description: Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
Study: NCT03952065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1/CTLA4 inhibitors
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1/CTLA4 inhibitors
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1/CTLA4 inhibitors
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
Study: NCT03344159

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
Description: At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
Description: At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac MRI (Gadolinium enhanced)
Description: At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
Study: NCT01852162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT03344159

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI (Gadolinium enhanced)
Description: At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
Study: NCT00979173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC480
Description: Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
Study: NCT02955277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECH: Tablet Enhancement of Cognition and Health protocol
Description: Cognitive training using touchscreen tablets (TECH protocol)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care or active standard care
Description: standard occupational therapy or 6-weekly group sessions playing board games and puzzles.
Study: NCT04212169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: multiple doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple doses
Study: NCT01603940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril
Description: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
Study: NCT02748564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study: NCT04559906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray and Stretch technique (Ethyl chloride)
Description: Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustain pressure release
Description: Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers.
Study: NCT02748564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01420640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower frequency, shorter period of Tai Chi
Description: 12 weeks of supervised Tai Chi classes, 1x/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher frequency, shorter period of Tai Chi
Description: 12 weeks of supervised Tai Chi classes, 2x/week
Study: NCT02748564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03761914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: galinpepimut-S
Description: * Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
Study: NCT01420640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shorter frequency, longer period of Tai Chi
Description: 24 weeks of supervised Tai Chi classes, 1x/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher frequency, longer period of Tai Chi
Description: 24 weeks of supervised Tai Chi classes, 2x/week
Study: NCT03761914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
Study: NCT01427387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01214447

Intervention type: OTHER
Intervention: No intervention
Description: Observational study - no intervention
Study: NCT01420640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 24 weeks of supervised aerobic exercise training, 2x/week
Study: NCT01597349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP01
Description: Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
Study: NCT01907048

Intervention type: BEHAVIORAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

Intervention type: BEHAVIORAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Survey to measure patient awareness and understanding of the key messages in the patient card.
Study: NCT04174053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enteric capsule
Description: Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
Study: NCT05157750

Intervention type: OTHER
Intervention: Recording of major clinical events
Description: During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.

Intervention type: OTHER
Intervention: Recording of major clinical events
Description: During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.

Intervention type: OTHER
Intervention: Recording of major clinical events
Description: During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
Study: NCT03134053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock-wave
Description: to treat painful and retracting scars
Study: NCT01214447

Intervention type: OTHER
Intervention: No intervention
Description: Observational study - no intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational study - no intervention